The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial.
 
Lauren Claire Brown
No Relationships to Disclose
 
Stephen James Luen
Research Funding - BeiGene (Inst); Roche (Inst)
 
Ramyar Molania
No Relationships to Disclose
 
Franco Caramia
No Relationships to Disclose
 
Peter Savas
Research Funding - Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Roche/Genentech
 
Courtney VanGeelen
No Relationships to Disclose
 
Nuria Chic
No Relationships to Disclose
 
Gini F. Fleming
Honoraria - Physicans' Education Resource
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Celldex (Inst); Compugen (Inst); Compugen (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); K-Group Beta (Inst); Merck (Inst); Molecular Templates (Inst); P{fizer (Inst); Pfizer (Inst); Plexxikon (Inst); Roche (Inst); Sermonix Pharmaceuticals (Inst); Syros Pharmaceuticals (Inst)
Other Relationship - AstraZeneca (Inst); Caris Life Sciences (Inst); DSI (Inst); Eisai (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie
 
Rosita Kammler
No Relationships to Disclose
 
Marco Colleoni
Research Funding - Roche (Inst)
 
Giuseppe Viale
Honoraria - Daiichi Sankyo Europe GmbH
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Dako; Menarini; MSD Oncology; Novartis; Roche/Genentech
Research Funding - AstraZeneca (Inst); Cepheid (Inst); Dako/Agilent Technologies (Inst); Roche/Genentech (Inst); Ventana Medical Systems (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Terence Paul Speed
No Relationships to Disclose
 
Meredith M. Regan
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Debiopharm Group (Inst); Ipsen (Inst); Tersera; Tolmar
Research Funding - AstraZeneca (Inst); Bayer (Inst); bioTheranostics (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); TerSera (Inst)
 
Prudence A. Francis
No Relationships to Disclose
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Lilly (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Tallac Therapeutics (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Roche Medical writing support